In myeloproliferative neoplasms the JAK-STAT signaling pathway can be inhibited with the JAK1/JAK2 inhibitor ruxolitinib and in rheumatoid arthritis with less selective JAK inhibitors such as tofacitinib and baricitinib [31]. Here, JAK2 is linked to myeloproliferative neoplasm.